

Fig. S2. The numbers of Th17 and Th22 cells in peripheral blood mononuclear cell (PBMC) samples analysed by flow cytometry. As representative samples, PBMC samples from a psoriatic patient (a) before and (b) after one week of betamethasone monotherapy and samples from another psoriatic patient (c) before and (d) after 1 week of calcipotriol/betamethasone combination therapy are shown. $CD4^+$ T cells were selected from PBMC samples (*first column*). Memory $CD4^+$ T cells were identified as $CD4^+$, CD45RA- T cells (*second column*). Th17 memory cells were identified from memory $CD4^+$ T cells as $CD4^+$, CD45RA-, CXCR3-, $CCR6^+$ cells (*third column*). Th22 memory cells were identified from Th17 memory cells as $CD4^+$, CD45RA-, CXCR3-, $CCR6^+$, $CCR10^+$ cells and (*fourth column*) and skin-homing Th17 cells as $CD4^+$, CD45RA-, CXCR3-, $CCR6^+$, CLA^+ cells (*fifth column*). Both topical therapies reduced the numbers of Th22 cells (*fourth column*: combination therapy from 10.6% to 7.45% and monotherapy from 9.52% to 4.64%) and skin homing CLA^+ Th17 cells (*fifth column*: combination therapy from 19.5% to 17.2% and monotherapy from 12.6% to 6.91%).